December 2019

Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, is currently conducting more than 120 research studies, including clinical trials of targeted therapies and novel immunotherapy approaches.

New studies aim to improve survival for patients with HER2+ breast cancer

Therapies that target the HER2 protein can be effective, particularly in early-stage HER2+ breast cancer, yet effective treatments for advanced and metastatic disease are needed. Providence Cancer Institute medical oncologists Alison Conlin, M.D., and David Page, M.D., lead two new studies for patients with HER2+ breast cancer: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab (neoHIP) Read More About These Studies

All current open studies:

Brain Cancer Breast Cancer Gastrointestinal Cancers  Genitourinary Cancers Gynecologic Cancers

Head and Neck Cancers Hematologic Cancers Lung Cancer Melanoma Phase 1 Trials

Find additional studies for many types of cancer in Multiple Tumor Types .

New studies are posted frequently - please check our  website  for a complete list of our current studies. For more information, call 503-215-2614.

Refer A Patient

Email Our Team

See All Open Studies

Earle A. Chiles Research Institute

Sign up to receive this newsletter

‌ ‌ ‌